Syros Pharmaceuticals, Inc. – NASDAQ:SYRS
Founder-led company
Syros Pharmaceuticals stock price today
$0.006
-0.20
-97.37%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Syros Pharmaceuticals stock price monthly change
-96.52%
month
Syros Pharmaceuticals stock price quarterly change
-96.52%
quarter
Syros Pharmaceuticals stock price yearly change
-97.14%
year
Syros Pharmaceuticals key metrics
Market Cap | 5.41M |
Enterprise value | N/A |
P/E | -0.37 |
EV/Sales | -4.49 |
EV/EBITDA | 0.76 |
Price/Sales | 0.61 |
Price/Book | 0.09 |
PEG ratio | N/A |
EPS | -5.00 |
Revenue | N/A |
EBITDA | -123.17M |
Income | -144.49M |
Revenue Q/Q | -100% |
Revenue Y/Y | -8.79% |
Profit margin | -441.74% |
Oper. margin | -667.78% |
Gross margin | 30.84% |
EBIT margin | -667.78% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSyros Pharmaceuticals stock price history
Syros Pharmaceuticals stock forecast
Syros Pharmaceuticals financial statements
Average Price Target
$5
Potential upside: 90809.09%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 2.83M | -36.25M | -1279.84% |
|---|---|---|---|
| Sep 2023 | 3.76M | -40.14M | -1067.07% |
| Dec 2023 | 386K | -64.38M | -16679.79% |
| Mar 2024 | 0 | -3.70M |
| Jun 2023 | 180982000 | 107.74M | 59.53% |
|---|---|---|---|
| Sep 2023 | 147795000 | 111.49M | 75.44% |
| Dec 2023 | 168174000 | 151.51M | 90.09% |
| Mar 2024 | 134728000 | 119.67M | 88.82% |
| Jun 2023 | -22.38M | 32.92M | 140K |
|---|---|---|---|
| Sep 2023 | -31.85M | 28.64M | -5K |
| Dec 2023 | -18.56M | 1.52M | 43.38M |
| Mar 2024 | -31.09M | -24.64M | -265K |
Syros Pharmaceuticals alternative data
| Aug 2023 | 117 |
|---|---|
| Sep 2023 | 117 |
| Oct 2023 | 117 |
| Nov 2023 | 117 |
| Dec 2023 | 117 |
| Jan 2024 | 117 |
| Feb 2024 | 117 |
| Mar 2024 | 117 |
| Apr 2024 | 117 |
| May 2024 | 68 |
| Jun 2024 | 68 |
| Jul 2024 | 68 |
Syros Pharmaceuticals other data
100.00%
+43.60%
of SYRS is owned by hedge funds
44
-17
9.27M
+5.71M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2024 | 0 | 10601 |
| Jun 2024 | 0 | 34837 |
| Sep 2024 | 200000 | 0 |
| Nov 2024 | 0 | 502202 |
| Dec 2024 | 0 | 37070 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | SIMONIAN NANCY A director | Common Stock | 37,070 | $0.27 | $10,009 | ||
Sale | SIMONIAN NANCY A director | Common Stock | 134,713 | $0.27 | $35,699 | ||
Sale | QUIRK GERALD E officer: Chief Legal & Complian.. | Common Stock | 46,657 | $0.22 | $10,311 | ||
Sale | STEPHENS KRISTIN officer: Chief Development Offi.. | Common Stock | 36,133 | $0.22 | $7,949 | ||
Sale | ROTH DAVID officer: Chief Me.. | Common Stock | 12,099 | $0.2 | $2,384 | ||
Sale | CHEE CONLEY director, officer: President & .. | Common Stock | 134,797 | $0.2 | $26,959 | ||
Sale | HAAS JASON officer: Chief Financial Officer | Common Stock | 137,803 | $0.21 | $28,939 | ||
Option | SIMONIAN NANCY A director | Common Stock | 40,125 | N/A | N/A | ||
Option | SIMONIAN NANCY A director | Restricted Stock Units | 40,125 | N/A | N/A | ||
Option | ROTH DAVID officer: Chief Me.. | Common Stock | 18,875 | N/A | N/A |
| Patent |
|---|
Grant Filling date: 16 Jan 2019 Issue date: 26 Apr 2022 |
Grant Filling date: 8 Sep 2017 Issue date: 15 Mar 2022 |
Application Filling date: 25 Aug 2021 Issue date: 17 Feb 2022 |
Application Filling date: 16 Jan 2019 Issue date: 6 Jan 2022 |
Application Filling date: 1 Nov 2019 Issue date: 30 Dec 2021 |
Application METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) Filling date: 1 Nov 2019 Issue date: 30 Dec 2021 |
Application Filling date: 16 Jan 2019 Issue date: 9 Dec 2021 |
Grant Filling date: 3 Jun 2016 Issue date: 21 Sep 2021 |
Application Filling date: 1 Jun 2021 Issue date: 16 Sep 2021 |
Grant Filling date: 3 Apr 2018 Issue date: 10 Aug 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Syros Pharmaceuticals stock today?
One share of Syros Pharmaceuticals stock can currently be purchased for approximately $0.01.
-
When is Syros Pharmaceuticals's next earnings date?
Unfortunately, Syros Pharmaceuticals's (SYRS) next earnings date is currently unknown.
-
Does Syros Pharmaceuticals pay dividends?
No, Syros Pharmaceuticals does not pay dividends.
-
How much money does Syros Pharmaceuticals make?
Syros Pharmaceuticals has a market capitalization of 5.41M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 33.23% to 9.94M US dollars.
-
What is Syros Pharmaceuticals's stock symbol?
Syros Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "SYRS".
-
What is Syros Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Syros Pharmaceuticals?
Shares of Syros Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Syros Pharmaceuticals's key executives?
Syros Pharmaceuticals's management team includes the following people:
- Dr. Nancy A. Simonian M.D. Pres, Chief Executive Officer & Director(age: 64, pay: $1,030,000)
- Dr. David A. Roth Chief Medical Officer(age: 62, pay: $713,030)
- Dr. Eric R. Olson Chief Scientific Officer(age: 67, pay: $696,420)
- Dr. Richard A. Young Ph.D. Scientific Founder, Member of Scientific Advisory Board & Director(age: 71, pay: $165,000)
-
Is Syros Pharmaceuticals founder-led company?
Yes, Syros Pharmaceuticals is a company led by its founder Dr. Richard A. Young Ph.D..
-
How many employees does Syros Pharmaceuticals have?
As Jul 2024, Syros Pharmaceuticals employs 68 workers, which is 42% less then previous quarter.
-
When Syros Pharmaceuticals went public?
Syros Pharmaceuticals, Inc. is publicly traded company for more then 9 years since IPO on 30 Jun 2016.
-
What is Syros Pharmaceuticals's official website?
The official website for Syros Pharmaceuticals is syros.com.
-
Where are Syros Pharmaceuticals's headquarters?
Syros Pharmaceuticals is headquartered at 35 CambridgePark Drive, Cambridge, MA.
-
How can i contact Syros Pharmaceuticals?
Syros Pharmaceuticals's mailing address is 35 CambridgePark Drive, Cambridge, MA and company can be reached via phone at +61 77441340.
-
What is Syros Pharmaceuticals stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Syros Pharmaceuticals in the last 12 months, the avarage price target is $5. The average price target represents a 90809.09% change from the last price of $0.01.
Syros Pharmaceuticals company profile:
Syros Pharmaceuticals, Inc.
syros.comExchange:
NASDAQ
Full time employees:
68
Industry:
Biotechnology
Sector:
Healthcare
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
35 CambridgePark Drive
Cambridge, MA 02140
Cambridge, MA 02140
CIK: 0001556263
ISIN: US87184Q2066
CUSIP: 87184Q107
